Samrat Pharmachem [SAMRATPH] vs Foseco India Limited [FOSECOIND] Detailed Stock Comparison
Samrat Pharmachem
BSE
Loading...
Foseco India Limited
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Samrat Pharmachem wins in 7 metrics, Foseco India Limited wins in 12 metrics, with 0 ties. Foseco India Limited appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Samrat Pharmachem | Foseco India Limited | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 20.00 | 43.67 | Samrat Pharmachem |
| Price-to-Book Ratio | 1.34 | 9.67 | Samrat Pharmachem |
| Debt-to-Equity Ratio | 13.81 | 0.42 | Foseco India Limited |
| PEG Ratio | -0.18 | 2.66 | Samrat Pharmachem |
| EV/EBITDA | 13.61 | 32.47 | Samrat Pharmachem |
| Profit Margin (TTM) | 1.72% | 14.05% | Foseco India Limited |
| Operating Margin (TTM) | -0.06% | 15.72% | Foseco India Limited |
| EBITDA Margin (TTM) | N/A | 15.72% | N/A |
| Return on Equity | 9.91% | 24.30% | Foseco India Limited |
| Return on Assets (TTM) | 5.85% | 11.97% | Foseco India Limited |
| Free Cash Flow (TTM) | $-105.99M | $267.09M | Foseco India Limited |
| Dividend Yield | 0.29% | 0.54% | Foseco India Limited |
| 1-Year Return | -44.72% | 19.83% | Foseco India Limited |
| Price-to-Sales Ratio (TTM) | 0.34 | 6.18 | Samrat Pharmachem |
| Enterprise Value | $1.06B | $32.86B | Foseco India Limited |
| EV/Revenue Ratio | 0.38 | 5.64 | Samrat Pharmachem |
| Gross Profit Margin (TTM) | 2.99% | 44.71% | Foseco India Limited |
| Revenue per Share (TTM) | $908 | $913 | Foseco India Limited |
| Earnings per Share (Diluted) | $15.59 | $128.17 | Foseco India Limited |
| Beta (Stock Volatility) | -0.40 | 0.06 | Samrat Pharmachem |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Samrat Pharmachem vs Foseco India Limited Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Samrat Pharmachem | -1.52% | 3.37% | -4.23% | -18.68% | -2.82% | -21.57% |
| Foseco India Limited | 0.75% | 2.07% | -10.82% | 12.04% | 68.68% | 35.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Samrat Pharmachem | -44.72% | -69.64% | 176.70% | 598.52% | 1,337.94% | 1,818.75% |
| Foseco India Limited | 19.83% | 193.06% | 375.18% | 312.81% | 1,116.61% | 1,398.14% |
News Based Sentiment: Samrat Pharmachem vs Foseco India Limited
Samrat Pharmachem
News based Sentiment: MIXED
October was a month of contrasting fortunes for Samrat Pharmachem, with a significant initial stock surge quickly followed by a decline to a 52-week low. This volatility, combined with mixed financial results, creates a complex investment picture that requires careful consideration.
Foseco India Limited
News based Sentiment: POSITIVE
Foseco India is demonstrating strong year-to-date returns and preparing for a key earnings release on November 6, 2025. While there's some short-term stock fluctuation, the long-term performance and upcoming results suggest a generally positive outlook for investors.
Performance & Financial Health Analysis: Samrat Pharmachem vs Foseco India Limited
| Metric | SAMRATPH | FOSECOIND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.03B | ₹35.95B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,850 | 6,270 |
| 90 Day Avg. Volume | 1,306 | 22,115 |
| Last Close | ₹307.00 | ₹5,639.00 |
| 52 Week Range | ₹289.00 - ₹425.00 | ₹3,205.00 - ₹6,846.00 |
| % from 52W High | -27.76% | -17.63% |
| All-Time High | ₹1,250.00 (Sep 19, 2022) | ₹6,846.00 (Sep 08, 2025) |
| % from All-Time High | -75.44% | -17.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.06% | 0.26% |
| Quarterly Earnings Growth | -0.06% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.14% |
| Operating Margin (TTM) | 0.00% | 0.16% |
| Return on Equity (TTM) | 0.10% | 0.24% |
| Debt to Equity (MRQ) | 13.81 | 0.42 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹232.02 | ₹578.81 |
| Cash per Share (MRQ) | ₹1.70 | ₹453.34 |
| Operating Cash Flow (TTM) | ₹1.26M | ₹629.85M |
| Levered Free Cash Flow (TTM) | ₹71.12M | ₹457.00M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.29% | 0.54% |
| Last 12-Month Dividend | ₹1.00 | ₹25.00 |
Valuation & Enterprise Metrics Analysis: Samrat Pharmachem vs Foseco India Limited
| Metric | SAMRATPH | FOSECOIND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 20.00 | 43.67 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -0.18 | 2.66 |
| Price to Sales (TTM) | 0.34 | 6.18 |
| Price to Book (MRQ) | 1.34 | 9.67 |
| Market Capitalization | ||
| Market Capitalization | ₹1.03B | ₹35.95B |
| Enterprise Value | ₹1.06B | ₹32.86B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.38 | 5.64 |
| Enterprise to EBITDA | 13.61 | 32.47 |
| Risk & Other Metrics | ||
| Beta | -0.40 | 0.06 |
| Book Value per Share (MRQ) | ₹232.02 | ₹578.81 |
Financial Statements Comparison: Samrat Pharmachem vs Foseco India Limited
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SAMRATPH | FOSECOIND |
|---|---|---|
| Revenue/Sales | ₹756.52M | ₹1.57B |
| Cost of Goods Sold | ₹733.90M | ₹869.49M |
| Gross Profit | ₹22.62M | ₹703.03M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-456,000 | ₹247.17M |
| EBITDA | ₹8.16M | ₹315.80M |
| Pre-Tax Income | ₹2.08M | ₹291.10M |
| Income Tax | ₹4.37M | ₹75.76M |
| Net Income (Profit) | ₹-2.29M | ₹215.34M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SAMRATPH | FOSECOIND |
|---|---|---|
| Cash & Equivalents | ₹483,000 | ₹906.63M |
| Total Current Assets | ₹1.03B | ₹4.30B |
| Total Current Liabilities | ₹495.83M | ₹1.38B |
| Long-Term Debt | ₹0 | ₹13.22M |
| Total Shareholders Equity | ₹718.00M | ₹3.43B |
| Retained Earnings | ₹687.11M | ₹2.80B |
| Property, Plant & Equipment | ₹0 | ₹11.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SAMRATPH | FOSECOIND |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SAMRATPH | FOSECOIND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,850 | 6,270 |
| Average Daily Volume (90 Day) | 1,306 | 22,115 |
| Shares Outstanding | 3.09M | 6.39M |
| Float Shares | 1.26M | 829,478 |
| % Held by Insiders | 0.59% | 0.86% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Samrat Pharmachem vs Foseco India Limited
| Metric | SAMRATPH | FOSECOIND |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹25.00 |
| Last 12-Month Dividend Yield | 0.29% | 0.54% |
| 3-Year Avg Annual Dividend | ₹1.67 | ₹21.67 |
| 3-Year Avg Dividend Yield | 0.17% | 0.60% |
| 3-Year Total Dividends | ₹5.00 | ₹65.00 |
| Ex-Dividend Date | Sep 19, 2024 | May 14, 2025 |